Phathom Pharmaceuticals, Inc.

NasdaqGS:PHAT Stock Report

Market Cap: US$280.0m

Phathom Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:PHAT Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
14 May 25BuyUS$24,462Frazier Life Sciences Management, LPCompany7,420US$3.32
12 May 25BuyUS$6,092,121Frazier Life Sciences Management, LPCompany1,912,780US$3.24
12 May 25BuyUS$152,917Frazier Life Sciences Management, LPCompany48,203US$3.62
07 May 25BuyUS$24,985Asit ParikhIndividual10,000US$2.60
07 Apr 25SellUS$16,740Molly HendersonIndividual3,678US$4.55
13 Mar 25BuyUS$44,200Asit ParikhIndividual10,000US$4.42
21 Jan 25SellUS$125,884Terrie CurranIndividual19,109US$6.59
21 Jan 25SellUS$51,957Azmi NabulsiIndividual7,886US$6.59
21 Jan 25SellUS$43,371Molly HendersonIndividual6,583US$6.59
19 Dec 24SellUS$10,328Molly HendersonIndividual1,291US$8.00
19 Dec 24SellUS$8,944Azmi NabulsiIndividual1,118US$8.00
13 Dec 24BuyUS$99,084Frank KarbeIndividual12,500US$7.93
13 Dec 24BuyUS$81,248Asit ParikhIndividual10,000US$8.12
15 Jul 24SellUS$396,699Terrie CurranIndividual33,848US$11.72
15 Jul 24SellUS$50,689Molly HendersonIndividual4,325US$11.72
15 Jul 24SellUS$127,760Azmi NabulsiIndividual10,901US$11.72

Insider Trading Volume

Insider Buying: PHAT insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of PHAT?
Owner TypeNumber of SharesOwnership Percentage
Private Companies18,8490.0263%
Individual Insiders2,659,4393.71%
VC/PE Firms22,990,86032.1%
Institutions46,051,78264.2%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19%.

Top Shareholders

Top 25 shareholders own 89.04% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
17.3%
Frazier Life Sciences Management, LP
12,029,480US$48.4m19%2.15%
10.7%
Medicxi Ventures (UK) LLP
7,464,572US$30.0m0%7.74%
10.1%
Jennison Associates LLC
7,042,325US$28.3m-0.29%0.02%
5.24%
Invesco Ltd.
3,647,952US$14.7m-0.56%no data
5.02%
Abingworth LLP
3,496,808US$14.1m0%14.27%
4.77%
BlackRock, Inc.
3,323,603US$13.4m-5.1%no data
3.99%
The Vanguard Group, Inc.
2,778,687US$11.2m-0.03%no data
3.61%
Ensign Peak Advisors, Inc.
2,514,284US$10.1m-0.51%0.02%
2.81%
New Enterprise Associates, Inc.
1,960,169US$7.9m0%0.48%
2.69%
Strategic Advisers LLC
1,875,803US$7.5m-7.64%no data
2.44%
Wasatch Advisors LP
1,701,627US$6.8m9.15%0.02%
2.07%
683 Capital Management, LLC
1,445,000US$5.8m41%0.57%
1.75%
David Socks
1,220,756US$4.9m0%no data
1.72%
Tang Capital Management, LLC
1,200,000US$4.8m140%0.24%
1.68%
Catalys Pacific
1,167,114US$4.7m0%3.06%
1.63%
Propel Bio Management, LLC
1,134,927US$4.6m178%5.46%
1.59%
GW&K Investment Management, LLC
1,104,308US$4.4m0.14%0.04%
1.47%
Morgan Stanley, Investment Banking and Brokerage Investments
1,022,496US$4.1m11.6%no data
1.46%
Geode Capital Management, LLC
1,016,423US$4.1m-0.2%no data
1.33%
Azmi Nabulsi
929,335US$3.7m0%no data
1.29%
State Street Global Advisors, Inc.
901,354US$3.6m-13.3%no data
1.16%
UBS Asset Management AG
807,322US$3.2m38.4%no data
1.15%
Avidity Partners Management, L.P.
800,000US$3.2m-42.5%0.66%
1.08%
Woodline Partners LP
751,692US$3.0m-25%0.02%
0.98%
Simplify Asset Management Inc.
681,935US$2.7m17.2%0.11%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/25 01:12
End of Day Share Price 2025/05/23 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Phathom Pharmaceuticals, Inc. is covered by 12 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullBMO Capital Markets Equity Research
Kristen KluskaCantor Fitzgerald & Co.
Chase KnickerbockerCraig-Hallum Capital Group LLC